2026-06-08T09:11:23Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1246302025-10-07T23:59:00Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Mazoteras Pardo, Victoria author Becerro De Bengoa Vallejo, Ricardo author Losa Iglesias, Marta Elena author López López, Daniel author Rodríguez Sanz, David author Casado Hernández, Israel author Calvo Lobo, César author Palomo López, Patricia author 2019-12-02 Background Hypertension is considered as a main risk factor for chronic kidney disease development and progression. Thus, the control and evaluation of this disease with new software and devices are especially important in patients who suffer from chronic kidney disease. Objective This study aimed to validate the QardioArm mobile device, which is used for blood pressure (BP) self-measurement in patients who suffer from chronic kidney disease, by following the European Society of Hypertension International Protocol 2 (ESH-IP2) guidelines. Methods A validation study was carried out by following the ESH-IP2 guidelines. A sample of 33 patients with chronic kidney disease self-measured their BP by using the QardioArm and Omron M3 Intellisense devices. Heart rate (HR), diastolic BP, and systolic BP were measured. Results The QardioArm fulfilled the ESH-IP2 validation criteria in patients who suffered from chronic kidney disease. Conclusions Thus, this study is considered as the first validation using a wireless upper arm oscillometric device connected to an app to measure BP and HR meeting the ESH-IP2 requirements in patients who suffer from chronic kidney disease. New validation studies following the ESH-IP2 guidelines should be carried out using different BP devices in patients with specific diseases. 1439-4456 10.2196/14686 https://hdl.handle.net/20.500.14352/124630 1438-8871 https://doi.org/10.2196/14686 https://www.jmir.org/2019/12/e14686 QardioArm Upper Arm Blood Pressure Monitor Against Omron M3 Upper Arm Blood Pressure Monitor in Patients With Chronic Kidney Disease: A Validation Study According to the European Society of Hypertension International Protocol Revision 2010